{
    "nctId": "NCT01399086",
    "briefTitle": "Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer",
    "officialTitle": "A Retrospective Study of Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer in Greece (The 'RESPONSE' Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 140,
    "primaryOutcomeMeasure": "Time to Progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with ER-positive and/or PgR-positive breast cancer who have failed at least one prior endocrine therapy, either as adjuvant treatment or for the treatment of advanced disease\n* Patients who have received treatment with fulvestrant for metastatic breast cancer and have completed/discontinued the treatment regardless of outcome/reason for discontinuation (except for treatment discontinuation for non-clinical reasons)\n* Patients who were at postmenopausal status at the time of treatment with fulvestrant\n\nExclusion Criteria:\n\n* Patients who are currently undergoing treatment with fulvestrant\n* Investigators/treating physicians with no available electronical or paper-based medical records",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}